Can-Fite BioPharma (CANF) Competitors $3.37 -0.09 (-2.72%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CANF vs. GNPX, ADXN, ERNA, BFRG, and NCNAShould you buy Can-Fite BioPharma stock or one of its competitors? MarketBeat compares Can-Fite BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Can-Fite BioPharma include Genprex (GNPX), Addex Therapeutics (ADXN), Ernexa Therapeutics (ERNA), Bullfrog AI (BFRG), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry. CANF vs. GNPXCANF vs. ADXNCANF vs. ERNACANF vs. BFRGCANF vs. NCNAHow does Can-Fite BioPharma compare to Genprex?Can-Fite BioPharma (NYSE:CANF) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation. Does the media favor CANF or GNPX? In the previous week, Can-Fite BioPharma had 2 more articles in the media than Genprex. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 2 mentions for Genprex. Can-Fite BioPharma's average media sentiment score of 0.86 beat Genprex's score of 0.71 indicating that Can-Fite BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genprex 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CANF or GNPX? Can-Fite BioPharma has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Genprex has a beta of -0.94, meaning that its share price is 194% less volatile than the broader market. Do analysts rate CANF or GNPX? Can-Fite BioPharma presently has a consensus price target of $42.50, suggesting a potential upside of 1,162.63%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Genprex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals and insiders hold more shares of CANF or GNPX? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 0.3% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings & valuation, CANF or GNPX? Can-Fite BioPharma has higher revenue and earnings than Genprex. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$405K5.44-$7.63M-$35.80N/AGenprexN/AN/A-$16.23M-$14.14N/A Is CANF or GNPX more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Genprex N/A -247.32%-176.73% SummaryCan-Fite BioPharma beats Genprex on 12 of the 14 factors compared between the two stocks.How does Can-Fite BioPharma compare to Addex Therapeutics?Addex Therapeutics (NASDAQ:ADXN) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Does the media prefer ADXN or CANF? In the previous week, Can-Fite BioPharma had 4 more articles in the media than Addex Therapeutics. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 0 mentions for Addex Therapeutics. Can-Fite BioPharma's average media sentiment score of 0.86 beat Addex Therapeutics' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media. Company Overall Sentiment Addex Therapeutics Neutral Can-Fite BioPharma Positive Is ADXN or CANF more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Addex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Addex TherapeuticsN/A -80.69% -69.69% Can-Fite BioPharma N/A N/A N/A Which has better valuation & earnings, ADXN or CANF? Addex Therapeutics has higher earnings, but lower revenue than Can-Fite BioPharma. Addex Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$210K41.47$8.02M-$5.74N/ACan-Fite BioPharma$405K5.44-$7.63M-$35.80N/A Do insiders and institutionals hold more shares of ADXN or CANF? 16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend ADXN or CANF? Can-Fite BioPharma has a consensus target price of $42.50, suggesting a potential upside of 1,162.63%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility & risk, ADXN or CANF? Addex Therapeutics has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. SummaryCan-Fite BioPharma beats Addex Therapeutics on 9 of the 15 factors compared between the two stocks.How does Can-Fite BioPharma compare to Ernexa Therapeutics?Can-Fite BioPharma (NYSE:CANF) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Does the media refer more to CANF or ERNA? In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 4 articles in the media. Can-Fite BioPharma's average media sentiment score of 0.86 beat Ernexa Therapeutics' score of 0.26 indicating that Can-Fite BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CANF or ERNA? Can-Fite BioPharma presently has a consensus price target of $42.50, indicating a potential upside of 1,162.63%. Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 146.69%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, CANF or ERNA? Can-Fite BioPharma has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Do insiders and institutionals hold more shares of CANF or ERNA? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CANF or ERNA more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Ernexa Therapeutics N/A -263.74%-151.16% Which has better valuation and earnings, CANF or ERNA? Can-Fite BioPharma has higher earnings, but lower revenue than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$405K5.44-$7.63M-$35.80N/AErnexa Therapeutics$580K24.53-$14.08M-$26.20N/A SummaryCan-Fite BioPharma beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.How does Can-Fite BioPharma compare to Bullfrog AI?Bullfrog AI (NASDAQ:BFRG) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Is BFRG or CANF more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -217.80% -174.57% Can-Fite BioPharma N/A N/A N/A Do analysts rate BFRG or CANF? Can-Fite BioPharma has a consensus target price of $42.50, indicating a potential upside of 1,162.63%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable earnings and valuation, BFRG or CANF? Bullfrog AI has higher earnings, but lower revenue than Can-Fite BioPharma. Bullfrog AI is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$120K68.58-$6.50M-$0.54N/ACan-Fite BioPharma$405K5.44-$7.63M-$35.80N/A Does the media refer more to BFRG or CANF? In the previous week, Can-Fite BioPharma had 3 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 1 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.38 beat Can-Fite BioPharma's score of 0.86 indicating that Bullfrog AI is being referred to more favorably in the media. Company Overall Sentiment Bullfrog AI Positive Can-Fite BioPharma Positive Which has more volatility & risk, BFRG or CANF? Bullfrog AI has a beta of -3, meaning that its share price is 400% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Do institutionals & insiders believe in BFRG or CANF? 1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 25.2% of Bullfrog AI shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryCan-Fite BioPharma beats Bullfrog AI on 9 of the 15 factors compared between the two stocks.How does Can-Fite BioPharma compare to NuCana?Can-Fite BioPharma (NYSE:CANF) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Is CANF or NCNA more profitable? Can-Fite BioPharma's return on equity of 0.00% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A NuCana N/A -153.61%-116.03% Do analysts prefer CANF or NCNA? Can-Fite BioPharma presently has a consensus price target of $42.50, indicating a potential upside of 1,162.63%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than NuCana.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals have more ownership in CANF or NCNA? 21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CANF or NCNA? In the previous week, Can-Fite BioPharma had 2 more articles in the media than NuCana. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 2 mentions for NuCana. NuCana's average media sentiment score of 1.50 beat Can-Fite BioPharma's score of 0.86 indicating that NuCana is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NuCana 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher earnings and valuation, CANF or NCNA? Can-Fite BioPharma has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$405K5.44-$7.63M-$35.80N/ANuCanaN/AN/A-$38.71M-$2.98N/A Which has more risk & volatility, CANF or NCNA? Can-Fite BioPharma has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, NuCana has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. SummaryCan-Fite BioPharma beats NuCana on 8 of the 14 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition ExportMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.21M$917.82M$6.30B$22.90BDividend YieldN/A4.84%2.80%4.13%P/E Ratio-1.881.4220.7929.83Price / Sales5.44115.77518.7989.43Price / CashN/A20.0743.1824.44Price / Book1.917.529.964.66Net Income-$7.63M-$3.91M$3.54B$1.07B7 Day Performance-3.55%-2.89%-0.19%-0.71%1 Month Performance15.27%73.53%-0.63%-0.58%1 Year Performance-83.75%121.50%34.10%27.01% Can-Fite BioPharma Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.8651 of 5 stars$3.37-2.7%$42.50+1,162.6%-83.6%$2.21M$405KN/A8GNPXGenprex0.7848 of 5 stars$0.83-1.8%N/A-94.5%$8.81MN/AN/A20ADXNAddex Therapeutics0.8536 of 5 stars$6.96+1.4%N/A-14.1%$8.45M$460KN/A30Positive NewsUpcoming EarningsGap DownERNAErnexa Therapeutics3.2222 of 5 stars$12.01+66.6%$30.00+149.8%-87.3%$8.41MN/AN/A10News CoverageEarnings ReportGap DownHigh Trading VolumeBFRGBullfrog AI0.7329 of 5 stars$0.62-5.6%N/A-63.9%$8.32M$120KN/A4Earnings Report Related Companies and Tools Related Companies Genprex Alternatives Addex Therapeutics Alternatives Ernexa Therapeutics Alternatives Bullfrog AI Alternatives NuCana Alternatives Creative Medical Technology Alternatives ObsEva Alternatives NKGen Biotech Alternatives Lunai Bioworks Alternatives Portage Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is...Brownstone Research | SponsoredNobody Understands Why Trump Is Invading Iran (here’s the answer)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decisi...Banyan Hill Publishing | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
